Scott Rocklage: Revolutionizing Medicine

Dr. Scott Rocklage received his Doctorate of Philosophy in Chemistry from the Massachusetts Institute of Technology and a Bachelor’s of Science in Chemistry from the University of California at Berkeley.

He is currently the Board Chairman of Relypsa, Semprus(acquired by Teleflex), and Achaogen. He is also a member of the Board of Associates at the Whitehead Institute and serves on the Boards of WaveRx, Pulmatrix, and Variation. Learn more about Scott Rocklage:  http://www.rennovia.com/team/scott-m-rocklage/ and http://5amventures.com/team/scott-m-rocklage-phd/

In the past, Doctor Rocklage was the Executive Chairman of Ilypsa (acquired by Amgen) and Miikana(acquired by EntreMed). Scott has over three decades of experience in the industry of Healthcare Management and joined 5AM Ventures in 2003 as a Venture Partner before becoming a Managing Partner in 2004.

Mr. Rocklage’s skills in his field combined with his strategic leadership responsibilities have resulted in the approval of three U.S New Drug Applications by the Food and Drug Admistration: Omniscan, Teslascan, and Cubicin. He holds over 30 United States patents as either an inventor or co inventor and is the author of over one hundred peer- reviewed publications.

Dr. Rocklage has worked with Cubist Pharmaceuticals as the Chairman and CEO. He was the President and Ceo of Nycomed Salutar, and the President, CEO, and Chairman of Nycomed Interventional. Mr.Rocklage has held several Research and Development positions with the companies Salutar and Catalytica.

While studying at the Massachusetts Institute of Technology, he conducted research in the lab of Richard R. Schrock, recipient of the Nobel Prize in Chemistry in 2005. His office is based in Boston, MA.

Read more: Scott Rocklage | LinkedIn

 

 

Leave a Reply